NCT03606967 — National Cancer Institute (NCI) neoantigen vaccine trial
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Registry record
| Registry ID | NCT03606967 ↗ |
|---|---|
| Lead sponsor | National Cancer Institute (NCI) |
| Collaborators | — |
| Phase | Phase 2 |
| Status | Recruiting |
| Indication | Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma |
| Enrollment | 86 participants (target) |
| Start date | 2021-04-13 |
| Primary completion | 2026-12-30 (est.) |
| Last registry update | 10 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03606967), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT03606967?
NCT03606967 (Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer) is registered on ClinicalTrials.gov as Phase 2, sponsored by National Cancer Institute (NCI).
Is NCT03606967 recruiting?
As of the 2026-08-10 registry update, NCT03606967 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03606967?
The lead sponsor is National Cancer Institute (NCI).
What condition does NCT03606967 study?
The registered conditions are Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma. Primary completion is listed as 2026-12-30 (estimated).
Are results available for NCT03606967?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03606967.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.